We conducted a secondary analysis of a multicenter, double-blinded RCT in which women with a singleton pregnancy were identified prior to 20 weeks with subclinical hypothyroidism or hypothyroxinemia and treated with thyroxine or placebo. Treatment did not affect outcome so the 2 groups were combined for this analysis and infants with anomalies (chromosomal or structural) or admission for intensive care were excluded. Our primary outcome was low IQ score (<85 at age 5 by WPPSI-III). Secondary outcomes include DAS-II scores at age 3, Bayley III score (age 1 and 2), Child Behavioral Checklist (age 3 and 5), and Conners' Rating ScalesRevised ADHD scores (age 4). Duration of BF was self-reported 2 years after delivery. Univariable analyses were performed to compare maternal characteristics and child outcomes based on BF (any vs. none).
In a large prospective cohort study of nullipara, participants completed the Edinburgh Postnatal Depression Scale (EPDS) during the first trimester and again at the third study visit (between 22 and 29 6/7 weeks). In the midtrimester, between these depression assessments, a subgroup underwent actigraphy and completed a sleep diary for 7 days. A high EPDS score was defined as an EPDS score > 10 or any thoughts of self harm. Sleep disturbances were defined as follows: short sleep duration < 7 hours, high fragmentation index >75%ile, high wake after sleep onset (WASO) >75%ile, elevated sleep onset latency >30 minutes, low time above light threshold 1000 lux (TALT) <25%ile, low sleep efficiency <80%. Univariable analyses were performed to investigate the association between maternal baseline characteristics, sleep disturbances and high depression scores later in pregnancy. All significant (P<0.05) covariates in univariable analysis were included in multivariable analysis. RESULTS: The study population for this analysis includes 778 women who had visit 3 EPDS scores and who underwent actigraphy assessment. This cohort represented a racially and ethnically diverse group of women with an average age of 27 years (Table) . At visit 3, 108 (13.9%) women had high EPDS scores. Univariable analyses demonstrated that these women were significantly more likely to be younger, single, publicly insured, smokers, diagnosed with a mental health condition prior to pregnancy, and to have high EPDS scores at the first study visit as compared to women with low scores at visit 3. Women with elevated sleep onset latency and low-sleep efficiency were significantly more likely to have high EPDS scores at visit 3 (Table) . However, in multivariable logistic regression, only preexisting mental health conditions (OR 3.7, confidence interval 2.2-12.0) and high EPDS scores at the first visit (OR 7.7, confidence interval 3.4-17.5) remained associated with high EPDS scores at visit 3. CONCLUSION: Objectively-measured sleep disturbances in the middle of pregnancy were not independently associated with high depression scores later in pregnancy.
Poster Session II OBJECTIVE: Methamphetamine is one of the most commonly used illicit drugs during pregnancy, highlighting the importance of understanding the risks associated with its use and adverse pregnancy outcomes. We sought to determine the association between methamphetamine use and pregnancy outcomes in a large cohort of US women. STUDY DESIGN: This was a retrospective cohort study of pregnancies in California from 2007 to 2011 using the California birth registry. Subjects were stratified into two groups: methamphetamines use during pregnancy versus no methamphetamine use. We assessed maternal demographics and characteristics in addition to pregnancy outcomes. Differences were analyzed by Pearson's chi-square, t-test, and logisticregression, with a¼0.05.
RESULTS:
Of 2,393,939 non-anomalous singleton pregnancies 23 to 42 weeks' gestation, 9,423 (0.39%) of women used methamphetamines during pregnancy. Methamphetamine users were more likely to be diagnosed with gestational hypertension or preeclampsia (10.6% vs 5.7%, p<0.001) and had an increased probability of severe maternal morbidity (4.2% vs 1.1%, p<0.001) ( Table 1) . Preterm delivery <37 weeks (29.4% vs 10.6% p<0.001) and neonatal hypoglycemia (1.9% vs 0.8%, p<0.001) were also more common among methamphetamine users. When adjusting for maternal characteristics and other substance use (tobacco, cannabis, and opioids), methamphetamine use was associated with multiple adverse maternal and neonatal outcomes (Figure 1) . CONCLUSION: Among a large cohort of pregnant women, methamphetamine use was associated with an increased odds of severe maternal morbidity, in addition to multiple other adverse maternal and neonatal outcomes. This reinforces the importance of identifying methamphetamine use during pregnancy to mitigate these adverse outcomes.
313 Medication-Assisted Treatment (MAT) in pregnancy: methadone and buprenorphine Cara Staszewski, Kimberly Herrera, Malini D. Persad, Victoria Ly, Diana Garretto, Jay Davis, David J. Garry Stony Brook University Hospital, Stony Brook, NY OBJECTIVE: To compare pregnancy outcomes in Medication-Assisted Treatment (MAT) with methadone or buprenorphine. STUDY DESIGN: A retrospective cohort of women receiving MAT with either methadone or buprenorphine were identified from delivery and newborn records at our tertiary care hospital over a 10-year period. Women were excluded with delivery less than 24 weeks, a multiple gestation, or a known anomalous fetus. Maternal demographics, medications, GA and mode of delivery, birthweight, newborn length of stay, and neonatal abstinence syndrome were extracted from the medical record. The study was IRB approved and
